Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
Dow
AstraZeneca
Baxter
Medtronic
Johnson and Johnson

Last Updated: October 23, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR RECLAST

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Reclast

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00171964 Efficacy and Tolerability of Zoledronic Acid With Radiotherapy in Pts With Advanced Osteolytic Bone Lesions Completed Novartis Pharmaceuticals Phase 4 2002-05-01 It is the aim of this multicentric clinical study to assess the efficacy and tolerability of zoledronic acid in combination with radiotherapy in patients with advanced osteolytic bone lesions in terms of the reduction of pain and analgesic consumption.
NCT00439647 Efficacy in Reducing Fractures and Safety of Zoledronic Acid in Men With Osteoporosis Completed Novartis Pharmaceuticals Phase 3 2006-12-01 This study will investigate if the drug zoledronic acid given once yearly is safe and has beneficial effects in treating osteoporosis by reducing bone loss and fractures in men with osteoporosis.
NCT00558012 Zoledronic Acid for Osteoporosis in the Elderly Completed National Institute on Aging (NIA) N/A 2007-12-01 This trial will examine the safety, efficacy and feasibility of a single dose of intravenous zoledronic acid in the maintenance of skeletal integrity for frail, institutionalized women, who are most at risk for the deleterious outcomes of osteoporosis. The investigators will test the hypothesis that in institutionalized elderly women a single dose of intravenous zoledronic acid therapy will: (1) be efficacious as demonstrated by stability or improvement in bone mass measurements and reductions in bone turnover; (2) be safe and feasible; and (3) provide estimates for vertebral and nonvertebral fracture reduction in this cohort for use in planning a future study.
NCT00558012 Zoledronic Acid for Osteoporosis in the Elderly Completed National Institutes of Health (NIH) N/A 2007-12-01 This trial will examine the safety, efficacy and feasibility of a single dose of intravenous zoledronic acid in the maintenance of skeletal integrity for frail, institutionalized women, who are most at risk for the deleterious outcomes of osteoporosis. The investigators will test the hypothesis that in institutionalized elderly women a single dose of intravenous zoledronic acid therapy will: (1) be efficacious as demonstrated by stability or improvement in bone mass measurements and reductions in bone turnover; (2) be safe and feasible; and (3) provide estimates for vertebral and nonvertebral fracture reduction in this cohort for use in planning a future study.
NCT00558012 Zoledronic Acid for Osteoporosis in the Elderly Completed University of Pittsburgh N/A 2007-12-01 This trial will examine the safety, efficacy and feasibility of a single dose of intravenous zoledronic acid in the maintenance of skeletal integrity for frail, institutionalized women, who are most at risk for the deleterious outcomes of osteoporosis. The investigators will test the hypothesis that in institutionalized elderly women a single dose of intravenous zoledronic acid therapy will: (1) be efficacious as demonstrated by stability or improvement in bone mass measurements and reductions in bone turnover; (2) be safe and feasible; and (3) provide estimates for vertebral and nonvertebral fracture reduction in this cohort for use in planning a future study.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Reclast

Condition Name

Condition Name for Reclast
Intervention Trials
Osteoporosis 3
Paget's Disease of the Bone 2
Bone Loss 2
Stage IB Pancreatic Cancer 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Reclast
Intervention Trials
Osteoporosis 6
Bone Diseases, Metabolic 2
Osteitis Deformans 2
Bone Diseases 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Reclast

Trials by Country

Trials by Country for Reclast
Location Trials
United States 12
Spain 2
United Kingdom 2
South Africa 2
Belgium 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Reclast
Location Trials
Georgia 2
Pennsylvania 2
Michigan 1
Arizona 1
Nebraska 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Reclast

Clinical Trial Phase

Clinical Trial Phase for Reclast
Clinical Trial Phase Trials
Phase 4 6
Phase 3 1
Phase 2 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Reclast
Clinical Trial Phase Trials
Completed 7
Not yet recruiting 1
Recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Reclast

Sponsor Name

Sponsor Name for Reclast
Sponsor Trials
Novartis Pharmaceuticals 5
University of Pittsburgh 2
National Institute on Aging (NIA) 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Reclast
Sponsor Trials
Other 9
Industry 7
NIH 5
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
Medtronic
Boehringer Ingelheim
Johnson and Johnson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.